Description of patients with eating disorders by general practitioners: a cohort study and focus on co-management with depression
Abstract
International guidelines often state that general practitioners (GPs) provide early management for most patients with eating disorders (EDs). Depressive disorders are often a comorbidity of EDs. The aims of this study were to describe in France the characteristics of people with all subcategories of EDs managed by their GPs and to study the management temporality between depression and all subcategories of EDs. We carried out a cohort study with the only French database available in general practice. 1310 patients aged 8 years or older were seen at least once for an ED by a GP participating in the database out of 355,848 patients. They had a mean age of 35.19 years, 82.67% were women. 41.6% had anorexia nervosa, 26.4% bulimia nervosa, and 32% an ED not otherwise specified. 32.3% had been managed at least once for depression. Benzodiazepines had been prescribed at least once for 73.9% of the patients treated for depression. Management for depression did not precede care for EDs. The frequency of visits for EDs was very low in our general practice-based sample. GPs could manage common early signs of depression and EDs, especially if they improved their communication skills and developed collaborative professional management. Background International guidelines often state that general practitioners (GPs) provide early management for most patients with eating disorders (EDs). GP management of EDs has not been studied in France. Depressive disorders are often a comorbidity of…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 355,848 participants or records.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.